T. Waldron

466 total citations
11 papers, 326 citations indexed

About

T. Waldron is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, T. Waldron has authored 11 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in T. Waldron's work include Prostate Cancer Treatment and Research (8 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Prostate Cancer Diagnosis and Treatment (4 papers). T. Waldron is often cited by papers focused on Prostate Cancer Treatment and Research (8 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Prostate Cancer Diagnosis and Treatment (4 papers). T. Waldron collaborates with scholars based in Canada and United States. T. Waldron's co-authors include Eric Winquist, Himu Lukka, Sébastien J. Hotte, Scott Berry, K.R. Desikan, Sundar Jagannath, Aubrey J. Hough, Madhav V. Dhodapkar, Bart Barlogie and David A. Siegel and has published in prestigious journals such as Radiotherapy and Oncology, BMC Cancer and Clinical Oncology.

In The Last Decade

T. Waldron

11 papers receiving 320 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T. Waldron Canada 9 176 100 81 45 43 11 326
Casely Ago Canada 6 140 0.8× 63 0.6× 184 2.3× 14 0.3× 27 0.6× 6 324
C. Stucchi Italy 13 127 0.7× 151 1.5× 84 1.0× 42 0.9× 92 2.1× 27 420
Ivana Russo Italy 12 150 0.9× 68 0.7× 103 1.3× 5 0.1× 22 0.5× 20 345
Ercole Mazzeo Italy 10 129 0.7× 38 0.4× 59 0.7× 6 0.1× 63 1.5× 19 261
H. Bülzebruck Germany 10 263 1.5× 67 0.7× 200 2.5× 20 0.4× 10 0.2× 23 400
Rajender Kumar Basher India 10 118 0.7× 28 0.3× 100 1.2× 15 0.3× 12 0.3× 44 268
Mario Di Staso Italy 10 149 0.8× 98 1.0× 117 1.4× 5 0.1× 38 0.9× 30 369
Daniele Scartoni Italy 9 212 1.2× 44 0.4× 76 0.9× 5 0.1× 82 1.9× 45 351
Hyung‐Sik Lee South Korea 10 105 0.6× 70 0.7× 176 2.2× 11 0.2× 49 1.1× 26 362
Shahin Shajahan United States 7 129 0.7× 103 1.0× 65 0.8× 4 0.1× 38 0.9× 9 316

Countries citing papers authored by T. Waldron

Since Specialization
Citations

This map shows the geographic impact of T. Waldron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Waldron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Waldron more than expected).

Fields of papers citing papers by T. Waldron

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Waldron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Waldron. The network helps show where T. Waldron may publish in the future.

Co-authorship network of co-authors of T. Waldron

This figure shows the co-authorship network connecting the top 25 collaborators of T. Waldron. A scholar is included among the top collaborators of T. Waldron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Waldron. T. Waldron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Canil, Christina, et al.. (2013). Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic review. Canadian Urological Association Journal. 4(3). 201–201. 17 indexed citations
2.
Lukka, Himu, T. Waldron, Joseph L. Chin, et al.. (2013). High-intensity focused ultrasound for prostate cancer: a practice guideline. Canadian Urological Association Journal. 4(4). 232–232. 12 indexed citations
3.
Hotte, Sébastien J., T. Waldron, Christina Canil, & Eric Winquist. (2012). Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline. Canadian Urological Association Journal. 1(1). 9 indexed citations
4.
Lukka, Himanshu, T. Waldron, Padraig Warde, et al.. (2010). High-intensity Focused Ultrasound for Prostate Cancer: a Systematic Review. Clinical Oncology. 23(2). 117–127. 56 indexed citations
5.
Morgan, Scott C., et al.. (2008). Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: A systematic review and meta-analysis. Radiotherapy and Oncology. 88(1). 1–9. 57 indexed citations
7.
Lukka, Himu, et al.. (2006). Maximal Androgen Blockade for the Treatment of Metastatic Prostate Cancer—A Systematic Review. Current Oncology. 13(3). 81–93. 25 indexed citations
8.
Berry, Scott, T. Waldron, Eric Winquist, & Himu Lukka. (2006). The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials.. PubMed. 13(4). 3180–8. 21 indexed citations
9.
Berry, Scott, T. Waldron, Eric Winquist, & Himu Lukka. (2005). The use of bisphosphonates in men with hormone-refractory prostate cancer. 2 indexed citations
10.
Berry, Sameer, et al.. (2005). 121 The use of bisphosphonates in men with hormone-refractory prostate cancer: A systematic review of randomized trials. Radiotherapy and Oncology. 76. S36–S36. 7 indexed citations
11.
Desikan, K.R., Madhav V. Dhodapkar, Aubrey J. Hough, et al.. (1997). Incidence and Impact of Light Chain Associated (AL) Amyloidosis on the Prognosis of Patients with Multiple Myeloma Treated with Autologous Transplantation. Leukemia & lymphoma. 27(3-4). 315–319. 84 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026